ArticleBMC neuroscience2026
A latent genetic factor underlies multiple component phenotypes of cerebral small vessel disease.
Article in BMC neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCerebral small vessel disease (cSVD) encompasses white matter hyperintensities (WMH), enlarged perivascular spaces (PVS), intracerebral hemorrhage (ICH), small vessel stroke (SVS), and cognitive impairment-phenotypes that frequently co-occur yet have been studied as independent genetic endpoints. Whether a shared genetic architecture underlies these co-occurring cSVD-related phenotypes remains unclear.
methodsWe applied Genomic SEM to GWAS summary statistics from six phenotypes (WMH, PVS, ICH, SVS, cognitive performance, systolic blood pressure), followed by multivariate association scanning, Bayesian fine-mapping (SuSiE/FINEMAP), gene-level (MAGMA) and transcriptome-wide (sCCA-TWAS/FOCUS) analyses, pathway enrichment, cell-type specificity (CELLECT) and spatial developmental mapping (gsMap).
resultsA common-factor model fit the data well (CFI = 1.00, SRMR = 0.061). The multivariate scan identified 1,423 genome-wide significant SNPs, resolving into 20 independent lead SNPs mapped to 14 distinct genomic loci, of which 2 were not detected at genome-wide significance in any constituent single-trait GWAS. Fine-mapping prioritized three high-confidence causal variants at EFEMP1, ICOSLG, and AC098824.6. Gene-level and transcriptome-wide analyses converged on effector genes at 17q25.1 (TRIM47/TRIM65), 10q24.33 (SH3PXD2A), and 2q33.1 (NBEAL1). MAGMA additionally identified APOE at 19q13.32. Pathway analysis highlighted epigenetic dysregulation, cellular senescence, and amyloid fiber formation. CELLECT identified vascular endothelial cells and pericytes as enriched cell types. gsMap revealed developmental enrichment in lung, kidney, and meninges exceeding brain tissue.
conclusionsThese findings delineate a coherent latent genetic structure linking multiple cSVD-related phenotypes, rooted in vascular wall cell biology, epigenetic regulation, and cellular senescence, with developmental origins spanning multiple organ microvascular beds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.